Latest news
NICE recommends FOTIVDA®▼ (tivozanib) as a new, first-line treatment for advanced renal cell carcinoma
Read moreWe are a dynamic, global speciality pharmaceutical company committed to bringing innovative medicines to patients.
Our therapy areas, which focus on oncology and rare diseases, help make a meaningful difference to patients’ lives.
We are constantly looking for highly talented individuals who, like us, are passionate and committed to helping patients live and embrace life.